The following is a summary of the Evotec SE (EVO) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Evotec reported a 4% increase with group revenues of €781.4 million for the year despite a cyber incident.

• Unpartnered R&D expenses reached €64.8 million signifying a focus on innovation.

• The adjusted EBITDA for the year was €66.4 million, which declined because of non-recoverable business losses and reduced capacity utilization.

• Gross margin slightly declined to 22.6% largely due to the effects of the cyber incident.

Business Progress:

• Evotec saw a remarkable growth in revenue from Just-Evotec Biologics and extended collaborations with BMS and Janssen.

• The company is focusing on driving profitable growth by Smart partnering, adjustment in organizational structure, and team buildup.

• Evotec is hopeful for significant margin improvements in the coming years.

• They are working on various operational improvement strategies and planning to introduce a new internal structure from Q1 2024.

• There is increased interest in their biologics portfolio and they are proceeding with multiple projects under the Sandoz contract.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.